Wall Street analyst estimates for LENSAR Inc (LNSR): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 0.67 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.05 | ||
| 2026-08-13 | $0.10 | $-0.17 | +160.6% |
| 2026-05-08 | $1.56 | $0.18 | +743.2% |
| 2026-03-31 | $-0.12 | $-0.07 | -80.7% |
| 2025-11-06 | $-0.31 | $-0.10 | -210.0% |
| 2025-08-07 | $-0.15 | $-0.08 | -87.5% |
| 2025-05-08 | $-2.32 | $-0.15 | -1446.7% |
| 2025-02-27 | $-1.61 | $-0.18 | -794.4% |
Valuation Ratios
| P/E Ratio | 5.44 |
| Price / Book | 5.70 |
| EV / EBITDA | 2.65 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $24.4M | $30.5M | $26.4M | $34.5M | $35.4M | $42.2M | $53.5M | $58.4M |
| Cost of Revenue | $14.8M | $17.3M | $12.3M | $16.6M | $15.4M | $21.1M | $27.6M | $31.3M |
| Gross Profit | $9.6M | $13.2M | $14.1M | $17.8M | $20.0M | $21.1M | $25.9M | $27.1M |
| Research & Development | $2.8M | $7.6M | $7.6M | $12.4M | $11.8M | $6.1M | $5.3M | $5.6M |
| Selling, General & Admin | $16.1M | $17.1M | $23.8M | $23.9M | $27.2M | $26.1M | $26.5M | $45.2M |
| Operating Expenses | $18.9M | $25.9M | $32.6M | $37.5M | $40.1M | $33.3M | $36.5M | $51.7M |
| Operating Income | -$9.3M | -$12.7M | -$18.5M | -$19.7M | -$20.2M | -$12.2M | -$10.7M | -$24.6M |
| EBITDA | -$4.7M | -$8.8M | -$15.4M | -$16.8M | -$16.5M | -$10.9M | -$3.0M | -$29.8M |
| Interest Expense | 0 | $2.0M | $1.3M | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$12.6M | -$14.7M | -$19.8M | -$19.6M | -$19.9M | -$14.4M | -$31.4M | -$34.3M |
| Income Tax | $20000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$12.6M | -$14.7M | -$19.8M | -$19.6M | -$19.9M | -$14.4M | -$31.4M | -$34.3M |
| EPS | $-11.77 | $-1.57 | $-1.81 | $-2.10 | $-1.96 | $-1.31 | $-2.73 | $-2.87 |
| EPS (Diluted) | $-11.77 | $-1.57 | $-1.81 | $-2.10 | $-1.96 | $-1.31 | $-2.73 | $-2.87 |
| Shares Outstanding (Diluted) | $1.1M | $10.6M | $10.9M | $9.4M | $10.2M | $11.0M | $11.5M | $12.0M |
Price
| Price | $7.09 |
| Market Cap | $87M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ANIK · ARAY · AVR · CRBP · CRDF · MXCT · OWLT
Explore sector: Healthcare · Medical - Devices
More sections of LNSR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks